Search Results

Teva’s ESG strategy guides how we advance health and equity, minimize our impact on the planet and dedicate ourselves to quality, ethics and transparency. It drives us to be responsible in all we do - take a look at how this came to life in 2021.

Find out more Discover how Teva’s work impacts economies and healthcare systems around the world in our Economic Impact Report Learn how we maintain an ethical and compliant business .  Explore a...

Dr David G Poplack, Director of Global HOPE, talks about the Teva partnership program which has had a life-changing impact in reducing child cancer deaths in Sub-Saharan Africa.

Dr Riad Dirani specializes in researching the clinical, economic and human impact of non-communicable diseases (NCDs), such as heart disease, stroke, cancer, asthma and diabetes. Riad outlines how his work is helping tackle an “invisible epidemic” and how his Dad’s unexpected experience with diabetes led him to a career in the pharma industry.

Read the latest and past featured stories from Teva Pharmaceuticals, and discover the newest developments of the health section.

Read the latest and past featured stories from Teva Pharmaceuticals, and discover the newest developments of the health section.

Interim data presented at the European Academy of Neurology 2022 shows that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more over the six-month period from the...

SANTA BARBARA, Calif. & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Direct Relief, the National Association of Free and Charitable Clinics (NAFC), and Teva Pharmaceuticals today launched a new program to...

Findings evaluate efficacy and safety of AUSTEDO in postmenopausal women with tardive dyskinesia (TD) for up to 3 years Two studies evaluate the psychological, social and physical impact of TD on...

Three posters evaluate the long-term safety and efficacy of AUSTEDO ® (deutetrabenazine) tablets as well as the physical, psychological, and social impact of tardive dyskinesia on patients One stud...

Environmental, Social and Governance (ESG) efforts integrated into business strategy with strengthened oversight, robust targets and sustainability-linked bond (SLB) Progress toward targets to...

16 presentations will examine safety and efficacy of AJOVY and AUSTEDO TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industrie...

National survey conducted by the Morehouse School of Medicine and Teva Pharmaceuticals shows intensified impacts among vulnerable populations driven by lack of access to care   About 50% of...

$5 billion bond is the largest of its kind from any sector and the first issued by a generic medicines company The bond is tied to targets that include improving access to medicines in low- and...

New Phase 3 RISE study data, post hoc analyses and open-label extension studies to be presented underscore company’s heritage in and commitment to mental health and neuroscience TEL AVIV, Israel &...

Extension analyses observed patients taking AJOVY experienced a reduction in migraine and headache days and evaluated disability and health-related quality of life Online symposium to highlight...

AMSTERDAM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today presented new epidemiology data on migraine from the State of Israel which indicate that socio-economic...

TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2020 Environmental, Social and Governance (ESG) Progress Report detailing the...

Findings evaluate safety, quality of life and patient-centered outcome measures up to 145 weeks TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals, a U.S. affiliate of Teva...

January 12, 2021 /3BL Media/  - Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has announced long-term environmental sustainability commitments and targets to provide direction and drive...

Open-label extension of the FOCUS Phase IIIb study examined changes in quality of life, health status, depressive symptoms and work productivity over 12 weeks Pooled Phase 3 results examined change...

TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today published its 2019 Environmental, Social and Governance (ESG) Progress Report, demonstrating the company’s social impact and responsibility performance. The report includes 2020 goals for specific topics and clear alignment with the United Nations Sustainable Development Goals. For the first time, an external reviewer validated select report content.

AJOVY data highlight efficacy and safety in difficult-to-treat migraine GALA open-label extension study evaluates 7-year efficacy and safety results of COPAXONE Teva Pharmaceutical Industries Ltd....

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the China National Medical Products Administration (NMPA) has approved AUSTEDO® (Deutetrabenazine Tablets) for the...

During these uncertain times, Teva’s commitment to improve the lives of patients is steadfast. Our latest Environmental, Social and Governance (ESG) Statement provides information on: Employee heal...